SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset
Posted innews Oncology Respiratory

SMARCA4-altered Resectable and Advanced NSCLC: Neoadjuvant Immunochemotherapy Works for Squamous, But KRAS+STK11/KEAP1 Co-mutations Define an Immune‑Cold High‑Risk Subset

Two contemporary series show that SMARCA4‑altered NSCLC is molecularly and clinically heterogeneous: squamous tumors have high pathologic responses to neoadjuvant immunochemotherapy, while non‑squamous tumors—especially those with co‑occurring KRAS and STK11/KEAP1 alterations—are immune‑cold and have poor outcomes despite chemoimmunotherapy.
AI-Derived Body Composition Analysis Unveils Muscle Volume, Metformin-Associated Adipose Effects, and the Obesity Paradox in NSCLC: Clinical and Molecular Insights
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news

AI-Derived Body Composition Analysis Unveils Muscle Volume, Metformin-Associated Adipose Effects, and the Obesity Paradox in NSCLC: Clinical and Molecular Insights

AI-driven analysis identifies muscle volume as a robust predictor of survival in NSCLC, highlights metformin-modulated adipose effects, and elucidates molecular links to the obesity paradox, informing personalized prognosis beyond BMI.
Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes
Posted inNeurology news Oncology

Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes

An international cohort of 2,052 NSCLC patients with leptomeningeal disease shows rising prevalence and improved survival in the modern treatment era. CNS‑penetrant tyrosine kinase inhibitors and immune checkpoint inhibitors are key drivers of delayed onset and longer leptomeningeal survival.
Impact of Antibiotics, Steroids, and PPIs on Survival in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
Posted inClinical Updates news Oncology Specialties

Impact of Antibiotics, Steroids, and PPIs on Survival in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

This nationwide cohort study reveals that certain antibiotics, higher-dose steroids, and proton pump inhibitors are associated with reduced overall survival in advanced NSCLC patients receiving first-line pembrolizumab, underscoring the importance of careful comedication monitoring during immunotherapy.